导读门脉性肺动脉高压（portopulmonary hypertension，PoPH）是门静脉高压的一种常见并发症，目前被归为肺动脉高压（pulmonary arterial hypertension，PAH）的一个亚型。

门脉性肺动脉高压（portopulmonary hypertension，PoPH）是门静脉高压的一种常见并发症，目前被归为肺动脉高压（pulmonary arterial hypertension，PAH）的一个亚型。

Charles D. Burger, MD: Portopulmonary hypertension is a subgroup of Group 1 pulmonary arterial hypertension [PAH], and it occurs in the setting of hepatic cirrhosis or end-stage liver disease ...

Demosthenes G. Papamatheakis 1, Ana Olga H. Mocumbi 2, Nick H. Kim 1, Jess Mandel 1, Schistosomiasis-associated pulmonary hypertension, Pulmonary Circulation, Vol. 4 ...

Intrapulmonary vascular dilatations occurred more commonly in patients with portopulmonary hypertension and were associated with decreased overall survival, according to study data published in ...

Portopulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH). PoPH occurs in approximately 15% of patients with PAH, and is reportedly found in 2-6% of patients with ...

Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension.

Portopulmonary hypertension is characterized by a mean pulmonary artery pressure > 25 mm Hg at rest or > 30 mm Hg with exercise, increased pulmonary vascular resistance (> 240 dynes/sec/cm-5), and ...

Patients with portopulmonary hypertension, for example, can come off PAH–targeted therapy after transplant, meaning some patients can even be cured of their portopulmonary hypertension with ...